ProPhase Labs (NASDAQ:PRPH) Stock Crosses Below 200 Day Moving Average – Here’s What Happened

ProPhase Labs, Inc. (NASDAQ:PRPH)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.44 and traded as low as $0.1301. ProPhase Labs shares last traded at $0.1356, with a volume of 68,986 shares changing hands.

ProPhase Labs Stock Performance

The stock has a market capitalization of $816,583.20, a P/E ratio of -0.03 and a beta of 0.09. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.14 and a current ratio of 0.14. The company’s fifty day simple moving average is $0.11 and its two-hundred day simple moving average is $0.44.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Susquehanna International Group LLP raised its holdings in ProPhase Labs by 290.1% in the 3rd quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after acquiring an additional 295,899 shares during the period. Accretive Wealth Partners LLC bought a new position in ProPhase Labs in the 3rd quarter valued at about $114,000. Finally, XTX Topco Ltd bought a new position in ProPhase Labs in the 2nd quarter valued at about $40,000. 9.45% of the stock is owned by institutional investors.

About ProPhase Labs

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.